A Contribution to Solve the Problem of the Need for Consolidative Radiotherapy after Intensive Chemotherapy in Advanced Stages of Hodgkin's Lymphoma—Analysis of a Quality Control Program Initiated by the Radiotherapy Reference Center of the German Hodgkin Study Group (GHSG)

Eich, Hans Theodor; Gossmann, Axel; Engert, Andreas; Kriz, Jan; Bredenfeld, Henning; Hansemann, Katja; Skripnitchenko, Roman; Brillant, Corinne; Pfistner, Beate; Staar, Susanne; Diehl, Volker; Müller, Rolf-Peter

doi:10.1016/j.ijrobp.2007.04.035

« Previous Next »International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1187-1192, 15 November 2007

A Contribution to Solve the Problem of the Need for Consolidative Radiotherapy after Intensive Chemotherapy in Advanced Stages of Hodgkin's Lymphoma—Analysis of a Quality Control Program Initiated by the Radiotherapy Reference Center of the German Hodgkin Study Group (GHSG)

Hans Theodor Eich, M.D., Ph.D.
- Department of Radiation Oncology, University of Cologne, Cologne, Germany
- Reprint requests to: Hans Theodor Eich, M.D., Ph.D., Department of Radiation Oncology, University of Cologne, Joseph-Stelzmann Str. 9, D-50924 Köln, Germany. Tel: (+49) 221-478-5449; Fax: (+49) 221-478-6158
Axel Gossmann, M.D.
- Department of Radiology, University of Cologne, Cologne, Germany
Andreas Engert, M.D.
- Department of Medical Oncology, University of Cologne, Cologne, Germany
Jan Kriz, M.D.
- Department of Radiation Oncology, University of Cologne, Cologne, Germany
Henning Bredenfeld, M.D.
- Department of Medical Oncology, University of Cologne, Cologne, Germany
Katja Hansemann, M.D.
- Department of Radiation Oncology, University of Cologne, Cologne, Germany
Roman Skripnitchenko, M.D.
- Department of Radiation Oncology, University of Cologne, Cologne, Germany
Corinne Brillant, Ph.D.
- Department of Medical Oncology, University of Cologne, Cologne, Germany
Beate Pfistner, Ph.D.
- Department of Medical Oncology, University of Cologne, Cologne, Germany
Susanne Staar, M.D.
- Department of Radiation Oncology, Klinikum Bremen Mitte, Bremen, Germany
Volker Diehl, M.D.
- Department of Medical Oncology, University of Cologne, Cologne, Germany
Rolf-Peter Müller, M.D.
- Department of Radiation Oncology, University of Cologne, Cologne, Germany

Received 7 March 2007; received in revised form 16 April 2007; accepted 16 April 2007. published online 20 August 2007.

Purpose

The role of radiotherapy (RT) after intensive chemotherapy in patients with advanced stage Hodgkin's lymphoma (HL) is still unclear. The German Hodgkin Study Group (GHSG) randomized HD12 trial was designed to test whether consolidative RT in the region of initial bulky disease and of residual disease is necessary after effective chemotherapy. A quality control program based on a multidisciplinary panel of radiation oncologists, radiologists, and medical oncologists who reviewed all patients' staging and restaging imaging was initiated.

Methods and Materials

A total of 1661 patients aged 16 to 65 years with HL in Stage IIB (large mediastinal mass and/or E-lesions) or Stage III to IV were randomized from January 1999 to January 2003 according to a factorial design between: 8 esc.BEACOPP + RT (arm A), 8 esc.BEACOPP non-RT (arm B), 4+4BEACOPP + RT (arm C), 4+4BEACOPP non-RT (arm D).

Results

In the fifth interim analysis, 1449 patients were eligible for the arm comparison with regard to RT. After a median observation time of 48 months the FFTF rate was 86% and the OS 92%. The FFTF was 95% in the RT arms A+C and 88% in the non-RT arms B+D: no sequential significant difference. One thousand and eighty four patients were evaluated by the panel. The panel defined initial bulky disease in 800 patients and residual disease in 600 patients. The panel recommended continuation of therapy according to the randomization for 934 of 1084 patients and additive RT independently from the randomization arm for 145 of 1084 patients.

Conclusions

The study showed that RT can be reduced substantially after effective chemotherapy. However, because of the irradiation of 10% of patients in the non-RT arms, equivalent effectiveness of a non-RT strategy cannot be proved. A substantial limitation of consolidative RT according to expert panel recommendations appears to be possible without reducing effectiveness.

Hodgkin's lymphoma, Consolidative radiotherapy, Panel, Quality assurance